

# **Certificate of Analysis**

Print Date: Jan 15th 2016

www.tocris.com

Product Name: Fludarabine Catalog No.: 3495 Batch No.: 1

CAS Number: 21679-14-1 EC Number: 244-525-5

IUPAC Name: 9-β-D-Arabinofuranosyl-2-fluoro-9*H*-purin-6-amine

#### 1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula:  $C_{10}H_{12}FN_5O_4$ 

**Batch Molecular Weight:** 285.23 **Physical Appearance:** White solid

Solubility: DMSO to 100 mM
Storage: Desiccate at +4°C

**Batch Molecular Structure:** 

### 2. ANALYTICAL DATA

Melting Point:Between 261 - 262°CHPLC:Shows 99.7% purity

<sup>1</sup>H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Found

Theoretical 42.11 4.24 24.55

4.19

24.42

42.15

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



## **Product Information**

Print Date: Jan 15<sup>th</sup> 2016

www.tocris.com

Product Name: Fludarabine Catalog No.: 3495 Batch No.: 1

CAS Number: 21679-14-1 EC Number: 244-525-5

IUPAC Name: 9- $\beta$ -D-Arabinofuranosyl-2-fluoro-9*H*-purin-6-amine

#### **Description:**

Purine analog that inhibits DNA synthesis. Exhibits antiproliferative activity (IC $_{50}$  = 1.54  $\mu M$  in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Inhibits cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in lymphocytes. Also displays anticancer activity against hematological malignancies in vivo.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>10</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>4</sub> Batch Molecular Weight: 285.23 Physical Appearance: White solid

Minimum Purity: >99%

#### **Batch Molecular Structure:**

Storage: Desiccate at +4°C

#### Solubility & Usage Info:

DMSO to 100 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

#### References:

**Bellosillo** *et al* (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood *94* 2836. PMID: 10515887.

Frank et al (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat.Med. 5 444. PMID: 10202937.

**Meng** et al (2007) Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur.J.Haematol. **79** 486. PMID: 17976186.

**Torella** *et al* (2007) Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia *in vivo* through specific inhibition of STAT-1 activation. Am.J.Physiol.Heart Circ.Physiol. **292** H2935. PMID: 17293493.